<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460365</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1200</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101200</ELocationID><Abstract><AbstractText Label="UNLABELLED">SARS-CoV-2, the causal agent of the COVID-19 pandemic, is characterized by rapid evolution, which poses a significant public health challenge. Effective vaccines that provide robust protection, elicit strong immune responses, exhibit favorable safety profiles, and enable cost-effective large-scale production are crucial. The RBD-Fc-based Betuvax-CoV-2 vaccine has previously demonstrated a favorable safety profile and induced a significant anti-SARS-CoV-2 humoral immune response in clinical trials. Due to the rapid evolution and emergence of new SARS-CoV-2 strains, the relevance of bivalent vaccine formulations has increased.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study compared the neutralizing capacity of monovalent and bivalent vaccine formulations against different SARS-CoV-2 strains detected with a SARS-CoV-2 microneutralization assay (MNT).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The monovalent Wuhan-based vaccine generated neutralizing antibodies against the Wuhan and Omicron BA.2 variants but not the distinct Omicron BQ.1 strain. Conversely, the monovalent BA.2-based vaccine induced neutralizing antibodies against both Omicron strains but not Wuhan. While the bivalent Wuhan and BA.2-based vaccine was effective against strains containing the same antigens, it was insufficient to neutralize the distinctive BQ.1 strain at a small dosage.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These findings suggest that the vaccine composition should closely match the circulating SARS-CoV-2 strain to elicit the optimal neutralizing antibody response and include the appropriate dosage. Moreover, this study did not find additional advantages of using the bivalent form over the monovalent form for the vaccination against a single prevailing SARS-CoV-2 strain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vakhrusheva</LastName><ForeName>Anna V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0001-7948-1254</Identifier><AffiliationInfo><Affiliation>Betuvax, 119571 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romanovskaya-Romanko</LastName><ForeName>Ekaterina A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0001-7560-398X</Identifier><AffiliationInfo><Affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stukova</LastName><ForeName>Marina A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-2127-3820</Identifier><AffiliationInfo><Affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sukhova</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-4572-1878</Identifier><AffiliationInfo><Affiliation>Betuvax, 119571 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuznetsova</LastName><ForeName>Ksenia S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0009-0002-5523-4907</Identifier><AffiliationInfo><Affiliation>Betuvax, 119571 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudriavtsev</LastName><ForeName>Aleksandr V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0002-3918-5618</Identifier><AffiliationInfo><Affiliation>Research Institute for Systems Biology and Medicine, 117246 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frolova</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Artgen Biotech, 119571 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanishin</LastName><ForeName>Taras V</ForeName><Initials>TV</Initials><AffiliationInfo><Affiliation>Betuvax, 119571 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasilnikov</LastName><ForeName>Igor V</ForeName><Initials>IV</Initials><Identifier Source="ORCID">0000-0002-5048-7828</Identifier><AffiliationInfo><Affiliation>Biotechnology Developments, 119571 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaev</LastName><ForeName>Artur A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0001-5848-5117</Identifier><AffiliationInfo><Affiliation>Artgen Biotech, 119571 Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Artgen Biotech</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">bivalent vaccines</Keyword><Keyword MajorTopicYN="N">subunit vaccines</Keyword></KeywordList><CoiStatement>A.A.I., I.V.K., M.E.F., A.V.K., and A.V.V. have author&amp;rsquo;s rights to the patents RU2749193 and RU2795160 (registered by Betuvax). E.A.R.-R. and M.A.S. had received payment from the company Betuvax for providing the experiment. A.A.I., I.V.K., M.E.F., A.V.K., A.V.V., and T.V.I. are shareholders of Betuvax. A.V.V., T.V.I., M.M.S., and K.S.K. are employees of Betuvax. A.A.I., as the founder of Artgen Biotech, provided the funding, participated in the design of this study, and in the decision to publish the results. The funders participated in the design of this study, the writing of the manuscript, and the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460365</ArticleId><ArticleId IdType="pmc">PMC11512205</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101200</ArticleId><ArticleId IdType="pii">vaccines12101200</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 Epidemiological Update.  [(accessed on 16 February 2024)].  Available online:  https://www.who.int/publications/m/item/covid-19-epidemiological-update-16-february-2024.</Citation></Reference><Reference><Citation>World Health Organization Data.  [(accessed on 12 June 2024)].  Available online:  https://data.who.int/dashboards/covid19/variants.</Citation></Reference><Reference><Citation>Kimura I., Yamasoba D., Nasser H., Ito H., Zahradnik J., Wu J., Fujita S., Uriu K., Sasaki J., Tamura T., et al. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics. J. Virol. 2023;97:e0101123. doi: 10.1128/jvi.01011-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01011-23</ArticleId><ArticleId IdType="pmc">PMC10781145</ArticleId><ArticleId IdType="pubmed">37796123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q., Li M., Ma L., Zhang C., Zhang H., Zhong H., Wen J., Wang Y., Yan Z., Xiong W., et al. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern. Front. Immunol. 2023;14:1195299. doi: 10.3389/fimmu.2023.1195299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1195299</ArticleId><ArticleId IdType="pmc">PMC10244545</ArticleId><ArticleId IdType="pubmed">37292197</ArticleId></ArticleIdList></Reference><Reference><Citation>Statement on the Antigen Composition of COVID-19 Vaccines.  [(accessed on 30 April 2024)].  Available online:  https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines.</Citation></Reference><Reference><Citation>Krasilnikov I.V., Kudriavtsev A.V., Vakhrusheva A.V., Frolova M.E., Ivanov A.V., Stukova M.A., Romanovskaya-Romanko E.A., Vasilyev K.A., Mushenkova N.V., Isaev A.A. Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2. Vaccines. 2022;10:69. doi: 10.3390/vaccines10010069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010069</ArticleId><ArticleId IdType="pmc">PMC8782008</ArticleId><ArticleId IdType="pubmed">35062730</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakhrusheva A.V., Kudriavtsev A.V., Kryuchkov N.A., Deev R.V., Frolova M.E., Blagodatskikh K.A., Djonovic M., Nedorubov A.A., Odintsova E., Ivanov A.V., et al. SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study. Vaccines. 2022;10:1290. doi: 10.3390/vaccines10081290.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081290</ArticleId><ArticleId IdType="pmc">PMC9412395</ArticleId><ArticleId IdType="pubmed">36016181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudriavtsev A.V., Vakhrusheva A.V., Kryuchkov N.A., Frolova M.E., Blagodatskikh K.A., Ivanishin T.V., Djonovic M., Romanovskaya-Romanko E.A., Kovalenko A.N., Lioznov D.A., et al. Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial. Vaccines. 2023;11:326. doi: 10.3390/vaccines11020326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020326</ArticleId><ArticleId IdType="pmc">PMC9965088</ArticleId><ArticleId IdType="pubmed">36851204</ArticleId></ArticleIdList></Reference><Reference><Citation>Branche A., Rouphael N., Diemert D., Falsey A., Losada C., Baden L.R., Frey S., Whitaker J., Little S., Anderson E., et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: The phase 2 randomized open-label COVAIL trial. Nat. Med. 2023;29:2334–2346. doi: 10.1038/s41591-023-02503-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02503-4</ArticleId><ArticleId IdType="pmc">PMC10504073</ArticleId><ArticleId IdType="pubmed">37640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z., Su Y., Zhang T., Xia N. A review of the safety and efficacy of current COVID-19 vaccines. Front. Med. 2022;16:39–55. doi: 10.1007/s11684-021-0893-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-021-0893-y</ArticleId><ArticleId IdType="pmc">PMC8815389</ArticleId><ArticleId IdType="pubmed">35122210</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmen J.M., Shrivastava S., Lu Z., Anderson A., Morrison E.B., Sankhala R.S., Chen W.-H., Chang W.C., Bolton J.S., Matyas G.R., et al. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. npj Vaccines. 2021;6:151. doi: 10.1038/s41541-021-00414-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00414-4</ArticleId><ArticleId IdType="pmc">PMC8668928</ArticleId><ArticleId IdType="pubmed">34903722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., Harper C., Vrbicky K., Walsh S.R., Essink B., Brosz A., McGhee N., Tomassini J.E., Chen X., Chang Y., et al. A Bivalent Omicron-Containing Booster Vaccine against COVID-19. N. Engl. J. Med. 2022;387:1279–1291. doi: 10.1056/NEJMoa2208343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208343</ArticleId><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N., Lustig Y., Indenbaum V., Zibly D., Joseph G., Asraf K., Weiss-Ottolenghi Y., Amit S., Kliker L., Elkader B.A., et al. Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: Randomized trial, 3-month follow-up. Clin. Microbiol. Infect. 2023;29:918–923. doi: 10.1016/j.cmi.2023.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.03.007</ArticleId><ArticleId IdType="pmc">PMC10010049</ArticleId><ArticleId IdType="pubmed">36921715</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier A.-R.Y., Miller J., Hachmann N.P., McMahan K., Liu J., Bondzie E.A., Gallup L., Rowe M., Schonberg E., Thai S., et al. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. N. Engl. J. Med. 2023;388:565–567. doi: 10.1056/NEJMc2213948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2213948</ArticleId><ArticleId IdType="pmc">PMC9847505</ArticleId><ArticleId IdType="pubmed">36630611</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S., Madewell Z.J., Liu M., Miao Y., Xiang S., Huo Y., Sarkar S., Chowdhury A., Longini I.M., Yang Y. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants. Vaccine. 2024;42:3389–3396. doi: 10.1016/j.vaccine.2024.04.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.04.049</ArticleId><ArticleId IdType="pubmed">38653679</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M.-Q., Li R., Weng Z.-Y., Song G. Relative effectiveness of bivalent COVID-19 vaccine: A systematic review and meta-analysis. Front. Med. 2024;10:1322396. doi: 10.3389/fmed.2023.1322396.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1322396</ArticleId><ArticleId IdType="pmc">PMC10879625</ArticleId><ArticleId IdType="pubmed">38384317</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal R., Buchan S.A., Nguyen L., Nasreen S., Austin P.C., Brown K.A., Gubbay J., Lee N., Schwartz K.L., Tadrous M., et al. Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study. J. Infect. Dis. 2023;229:394–397. doi: 10.1093/infdis/jiad419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad419</ArticleId><ArticleId IdType="pmc">PMC10873169</ArticleId><ArticleId IdType="pubmed">37798119</ArticleId></ArticleIdList></Reference><Reference><Citation>Auvigne V., Tchuem C.R.T., Schaeffer J., Vaux S., Du Chatelet I.P. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines—A matched cohort study in France. Vaccine. 2023;41:5490–5493. doi: 10.1016/j.vaccine.2023.07.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.071</ArticleId><ArticleId IdType="pubmed">37541823</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.-Y., Lin C.-Y., Chi H., Weng S.-L., Li S.-T., Tai Y.-L., Huang Y.-N., Huang H., Lin C.-H., Chiu N.-C. The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report. Life. 2023;13:2094. doi: 10.3390/life13102094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13102094</ArticleId><ArticleId IdType="pmc">PMC10608313</ArticleId><ArticleId IdType="pubmed">37895475</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Bretones M., Fouchier R.A., Koopmans M.P., van Nierop G.P. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. J. Clin. Investig. 2023;133:e162192. doi: 10.1172/JCI162192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI162192</ArticleId><ArticleId IdType="pmc">PMC9797340</ArticleId><ArticleId IdType="pubmed">36594464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>